Candel Therapeutics, Inc. (CADL) 10-Year Financial Performance & Capital Metrics

CADL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.Show more

Revenue $0
EBITDA -$32M +13.5%
Net Income -$55M -45.4%
EPS (Diluted) -1.74 -32.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -139.56% -11.2%
ROIC -
Debt/Equity 0.20 -88.6%
Interest Coverage -15.97 +78.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM56.4%

EPS CAGR

10Y-

5Y-

3Y-

TTM72.92%

ROCE

10Y Avg-48.32%

5Y Avg-53.92%

3Y Avg-63.47%

Latest-69.27%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	125K	125K	125K	125K	0	0
Revenue Growth %	-	0%	0%	0%	-1%	-
Cost of Goods Sold+	6.61M	0	14.59M	0	23.98M	990K
COGS % of Revenue	52.86%	-	116.75%	-	-	-
Gross Profit+	-6.48M	125K	-14.47M	125K	-23.98M	-990K
Gross Margin %	-51.86%	1%	-115.75%	1%	-	-
Gross Profit Growth %	-	1.02%	-116.75%	1.01%	-192.84%	0.96%
Operating Expenses+	2.56M	13.94M	11.26M	34.85M	14.41M	32.38M
OpEx % of Revenue	20.44%	111.48%	90.06%	278.78%	-	-
Selling, General & Admin	2.56M	5.99M	11.26M	14.06M	14.41M	14.06M
SG&A % of Revenue	20.44%	47.94%	90.06%	112.48%	-	-
Research & Development	6.61M	8.75M	15.18M	20.79M	24.51M	19.31M
R&D % of Revenue	52.86%	70.03%	121.42%	166.3%	-	-
Other Operating Expenses	-6.61M	-812K	-15.18M	0	-24.51M	-990K
Operating Income+	-9.04M	-13.81M	-25.73M	-34.72M	-38.39M	-33.37M
Operating Margin %	-72.3%	-110.48%	-205.81%	-277.78%	-	-
Operating Income Growth %	-	-0.53%	-0.86%	-0.35%	-0.11%	0.13%
EBITDA+	-8.99M	-13.72M	-25.49M	-33.94M	-37.43M	-32.38M
EBITDA Margin %	-71.95%	-109.75%	-203.95%	-271.55%	-	-
EBITDA Growth %	-	-0.53%	-0.86%	-0.33%	-0.1%	0.13%
D&A (Non-Cash Add-back)	43K	91K	232K	778K	960K	990K
EBIT	-9.04M	-13.81M	-25.73M	-17.09M	-38.39M	-53.09M
Net Interest Income+	1.07M	111K	-53K	-490K	-514K	-1M
Interest Income	1.07M	111K	0	1.22M	0	1.09M
Interest Expense	0	0	53K	1.71M	514K	2.09M
Other Income/Expense	797K	-3.87M	-10.4M	15.93M	452K	-21.81M
Pretax Income+	-8.24M	-17.68M	-36.12M	-18.79M	-37.94M	-55.18M
Pretax Margin %	-65.92%	-141.44%	-288.99%	-150.35%	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-8.24M	-17.68M	-36.12M	-18.79M	-37.94M	-55.18M
Net Margin %	-65.92%	-141.44%	-288.99%	-150.35%	-	-
Net Income Growth %	-	-1.15%	-1.04%	0.48%	-1.02%	-0.45%
Net Income (Continuing)	-8.24M	-17.68M	-36.12M	-18.79M	-37.94M	-55.18M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.43	-1.18	-1.26	-0.10	-1.31	-1.74
EPS Growth %	-	-1.74%	-0.07%	0.92%	-12.18%	-0.33%
EPS (Basic)	-0.43	-1.18	-1.26	-0.10	-1.31	-1.74
Diluted Shares Outstanding	18.71M	18.71M	28.69M	28.82M	28.94M	31.68M
Basic Shares Outstanding	18.71M	18.71M	28.69M	28.82M	28.94M	31.68M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	45.21M	35.15M	84.94M	71.94M	36.8M	103.8M
Cash & Short-Term Investments	45.06M	35.05M	82.64M	70.06M	35.41M	102.65M
Cash Only	5.18M	35.05M	82.64M	70.06M	35.41M	102.65M
Short-Term Investments	39.88M	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	2.3M	1.89M	1.38M	0
Total Non-Current Assets+	691K	3.14M	4.26M	6.57M	4.4M	3.06M
Property, Plant & Equipment	425K	2.79M	3.84M	5.48M	4.02M	2.73M
Fixed Asset Turnover	0.29x	0.04x	0.03x	0.02x	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	266K	0	424K	266K	0	0
Other Non-Current Assets	0	349K	0	0	382K	329K
Total Assets+	45.9M	38.28M	89.2M	78.52M	41.2M	106.87M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	-	-
Asset Growth %	-	-0.17%	1.33%	-0.12%	-0.48%	1.59%
Total Current Liabilities+	1.41M	4.71M	5.36M	5.62M	14.18M	37.53M
Accounts Payable	218K	921K	1.59M	380K	422K	237K
Days Payables Outstanding	12.04	-	39.77	-	6.42	87.38
Short-Term Debt	0	463K	0	464K	8.89M	9.89M
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	615K	187K	1.68M	2.12M	2.34M	22.11M
Current Ratio	32.06x	7.46x	15.84x	12.81x	2.59x	2.77x
Quick Ratio	32.06x	7.46x	15.84x	12.81x	2.59x	2.77x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	52.53M	57.13M	19.71M	25.19M	14.27M	3.01M
Long-Term Debt	420K	483K	560K	20.85M	12.38M	2.6M
Capital Lease Obligations	0	0	0	1.49M	973K	407K
Deferred Tax Liabilities	0	0	0	828K	0	0
Other Non-Current Liabilities	51.86M	56.52M	19.15M	1.88M	916K	0
Total Liabilities	53.94M	61.84M	25.07M	30.8M	28.46M	40.54M
Total Debt+	420K	946K	560K	22.8M	22.76M	13.47M
Net Debt	-4.76M	-34.11M	-82.08M	-47.26M	-12.65M	-89.18M
Debt / Equity	-	-	0.01x	0.48x	1.79x	0.20x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-485.40x	-20.33x	-74.69x	-15.97x
Total Equity+	-8.04M	-23.56M	64.14M	47.71M	12.74M	66.33M
Equity Growth %	-	-1.93%	3.72%	-0.26%	-0.73%	4.2%
Book Value per Share	-0.43	-1.26	2.24	1.66	0.44	2.09
Total Shareholders' Equity	-8.04M	-23.56M	64.14M	47.71M	12.74M	66.33M
Common Stock	116K	116K	286K	290K	290K	469K
Retained Earnings	-26.49M	-44.17M	-80.3M	-99.09M	-137.03M	-192.21M
Treasury Stock	-18.19M	0	0	-448K	-448K	-448K
Accumulated OCI	-19K	0	-89.2M	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.18M	-9.07M	-22.22M	-31.42M	-34.24M	-27.02M
Operating CF Margin %	-41.42%	-72.57%	-177.74%	-251.35%	-	-
Operating CF Growth %	-	-0.75%	-1.45%	-0.41%	-0.09%	0.21%
Net Income	-8.24M	-17.68M	-36.12M	-18.79M	-37.94M	-55.18M
Depreciation & Amortization	43K	91K	232K	778K	1.28M	990K
Stock-Based Compensation	400K	2.11M	2.96M	2.31M	3.09M	5.31M
Deferred Taxes	0	0	11.51M	0	0	0
Other Non-Cash Items	2.11M	4.64M	76K	-15.78M	-301K	21.51M
Working Capital Changes	513K	1.77M	-876K	71K	-378K	346K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	13K	289K	669K	-1.21M	0	-185K
Cash from Investing+	-35.74M	38.45M	-1.83M	-1.3M	-280K	-16K
Capital Expenditures	-159K	-1.48M	-1.83M	-1.3M	-457K	-16K
CapEx % of Revenue	1.27%	11.81%	14.68%	10.38%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	177K	0
Cash from Financing+	21.98M	490K	71.8M	19.97M	-121K	94.28M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	1K	30K	465K	64K	0	1.69M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-5.34M	-10.55M	-24.05M	-32.72M	-34.7M	-27.04M
FCF Margin %	-42.69%	-84.38%	-192.42%	-261.73%	-	-
FCF Growth %	-	-0.98%	-1.28%	-0.36%	-0.06%	0.22%
FCF per Share	-0.29	-0.56	-0.84	-1.14	-1.20	-0.85
FCF Conversion (FCF/Net Income)	0.63x	0.51x	0.62x	1.67x	0.90x	0.49x
Interest Paid	0	0	0	1.15M	2.15M	0
Taxes Paid	59K	93K	29K	183K	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-178.06%	-33.61%	-125.5%	-139.56%
Return on Invested Capital (ROIC)	-	-	-	-	-10470.27%	-
Gross Margin	-5185.6%	100%	-11575.2%	100%	-	-
Net Margin	-6592%	-14144%	-28899.2%	-15035.2%	-	-
Debt / Equity	-	-	0.01x	0.48x	1.79x	0.20x
Interest Coverage	-	-	-485.40x	-20.33x	-74.69x	-15.97x
FCF Conversion	0.63x	0.51x	0.62x	1.67x	0.90x	0.49x
Revenue Growth	-	0%	0%	0%	-100%	-

Frequently Asked Questions

Growth & Financials

Candel Therapeutics, Inc. (CADL) grew revenue by 0.0% over the past year. Growth has been modest.

Candel Therapeutics, Inc. (CADL) reported a net loss of $22.8M for fiscal year 2024.

Dividend & Returns

Candel Therapeutics, Inc. (CADL) has a return on equity (ROE) of -139.6%. Negative ROE indicates the company is unprofitable.

Candel Therapeutics, Inc. (CADL) had negative free cash flow of $33.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener